What are the ACE guideline recommendations for controlling blood glucose in diabetes?

Blood Glucose Control According to AACE/ACE Guidelines

The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) recommend targeting an A1C <6.5% for most patients with diabetes, which is more stringent than other guidelines, with treatment selection based on baseline A1C level and prioritizing agents that minimize hypoglycemia and weight gain. 1

Glycemic Targets

The AACE/ACE guidelines establish specific glycemic goals that differ from other organizations:

• A1C target: <6.5% (compared to ADA's <7.0%) 1, 2
• Preprandial plasma glucose: 90-130 mg/dL (5.0-7.2 mmol/L) 3
• Peak postprandial plasma glucose: <180 mg/dL (10.0 mmol/L) 3

These targets should be individualized based on patient factors including duration of diabetes, age, life expectancy, comorbidities, hypoglycemia risk, and patient preferences, but the default starting point is more aggressive than ADA recommendations. 1

Treatment Algorithm Based on Entry A1C

For A1C <7.5%

Initiate monotherapy with one of the following preferred agents: 1

• Metformin (first-line unless contraindicated)
• GLP-1 receptor agonist
• DPP-4 inhibitor
• SGLT2 inhibitor
• α-glucosidase inhibitor

Alternative agents (use with caution due to side effects): 1

• TZDs (thiazolidinediones)
• Sulfonylureas (least desirable due to hypoglycemia risk)
• Glinides (least desirable due to hypoglycemia risk)

For A1C 7.5-9.0%

Initiate dual therapy immediately: 1

• Metformin (unless contraindicated) PLUS a second agent
• Preferred second agents (prioritize those with low hypoglycemia risk and weight neutrality/loss):
  • GLP-1 receptor agonists
  • SGLT2 inhibitors
  • DPP-4 inhibitors
• Alternative second agents:
  • TZDs
  • Basal insulin
• Least desirable alternatives:
  • Sulfonylureas (hypoglycemia risk)
  • Glinides (hypoglycemia risk)

For A1C >9.0% with Symptomatic Hyperglycemia

Initiate insulin therapy immediately, alone or combined with metformin or other oral agents. 1

This aggressive approach differs from stepwise intensification and reflects the AACE/ACE philosophy of achieving glycemic control rapidly to prevent complications. 1

Cardiovascular and Renal Considerations

For patients with established cardiovascular disease or high cardiovascular risk, prioritize agents with proven cardiovascular benefits: 4

• Liraglutide (GLP-1 RA with CV mortality reduction)
• Semaglutide (GLP-1 RA with CV mortality reduction)
• Empagliflozin (SGLT2i with CV mortality reduction)
• Canagliflozin (SGLT2i with CV benefits)

These agents should be incorporated early after metformin, even if glycemic targets are being met, when cardiovascular protection is a priority. 4

Monitoring and Treatment Intensification

Blood glucose monitoring frequency: 3

• Type 1 diabetes: ≥3 times daily
• Type 2 diabetes on insulin or sulfonylureas: Sufficient frequency to achieve glycemic goals and detect hypoglycemia
• Type 2 diabetes on other agents: As needed to guide therapy adjustments

Treatment intensification timeline: 1

• Reassess every 3 months if not at glycemic goal
• Adjust medications promptly rather than waiting extended periods
• This contrasts with more conservative approaches that allow longer observation periods

Hypoglycemia Management

Definition and treatment thresholds: 1

• Hypoglycemia defined as blood glucose <70 mg/dL
• Treat immediately with 15-20g rapidly absorbed glucose
• Recheck in 15 minutes and repeat treatment if still <70 mg/dL
• Follow with meal or snack to prevent recurrence

Medication selection to minimize hypoglycemia: 1

• Avoid sulfonylureas and glinides when possible
• Prefer GLP-1 RAs, SGLT2is, DPP-4is, and metformin (glucose-dependent mechanisms)
• Use insulin analogs (glargine, detemir) over NPH insulin
• Use rapid-acting insulin analogs (lispro, aspart, glulisine) over regular insulin

Type 1 Diabetes Specific Recommendations

Insulin regimen: 1

• Long-acting basal insulin analogs (glargine or detemir) preferred over NPH
• Rapid-acting insulin analogs preferred over regular insulin for prandial coverage
• Basal-bolus regimens recommended for intensive therapy
• Premixed insulins may be considered only when adherence to complex regimens is problematic

Key Differences from ADA Guidelines

The AACE/ACE approach is more aggressive and specialist-oriented: 2

1. Lower A1C target (6.5% vs 7.0%)
2. Earlier combination therapy (dual therapy at A1C 7.5% vs stepwise at 3-month intervals)
3. Broader first-line options beyond metformin monotherapy
4. Stronger emphasis on avoiding hypoglycemia and weight gain in medication selection hierarchy
5. More rapid treatment intensification rather than prolonged observation periods

Common Pitfalls to Avoid

• Do not delay intensification when A1C remains above target after 3 months 1
• Do not use sulfonylureas as preferred agents despite their efficacy and low cost, due to hypoglycemia risk 1
• Do not ignore cardiovascular risk when selecting glucose-lowering agents in high-risk patients 4
• Do not use A1C alone for monitoring—incorporate self-monitoring blood glucose data and continuous glucose monitoring when appropriate 5
• Do not apply the same aggressive targets to frail elderly patients or those with limited life expectancy—individualize appropriately 1